Immune-Onc Therapeutics Inc. logo

Immune-Onc Therapeutics Inc.

Dedicated to the discovery and development of novel biologic treatments for cancer patients Immune-Onc Therapeutics, Inc. is a startup biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment.

Immune-Onc was co-founded by Charlene Liao and Guo-Liang Yu. Dr. Liao was Project Team Leader at Genentech, where she spent nearly 14 years leading oncology and immunology drug development programs. Dr. Yu was the co-founder and CEO of Epitomics Inc., an antibody company acquired by Abcam for $170 million.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.immune-onc.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1059 East Meadow Cir.,CA 094303
Palo Alto
United States
Email
Contact Number
+1 650-460-8898

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/immune-onc-therapeutics” connections=”true” suffix=””]

In March 2017, Immune-Onc acquire the exclusive global rights to develop and commercialize novel biotherapeutics with applications
in cancer immunotherapy and other diseases from Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center (_MSKÓ). In addition, Immune-Onc and Einstein have entered into a multi-year research collaboration to discover and develop a new generation of biotherapeutics that modulate the immune system.

In Sep 2016, Immune-Onc raised $7 Mn in Series A financing round led by Fame Mount Limited and CLI Ventures. The financing will support discovery and development of novel antibodies with breakthrough potential in the area of cancer immunotherapy.